Head-to-head · WeighScore
Welling Health vs Zealthy
The verdict
Welling Health takes it — 68.3/100 to 46.7/100.
Welling Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Welling Health is a clinician-led metabolic clinic offering compounded GLP-1 therapy on one transparent flat monthly rate: semaglutide from $190/month and tirzepatide from $275/month, with all doses,…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Welling Health | Zealthy |
|---|---|---|
| WeighScore | 68.3/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #149 | #496 |
| Semaglutide | $190/mo (compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $275/mo (compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | All 50 states | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #149 · C
Strengths
- Transparent flat monthly rate — $190 semaglutide / $275 tirzepatide, all doses, no insurance or hidden fees
- LegitScript-certified 503A pharmacy with US-licensed clinicians in all 50 states and a named legal entity
- Streak discounts cut up to 30% — semaglutide as low as $133/month for logging meals consistently
- Free shipping, free AI macro-tracker app, and 24-hour intake review
Where it loses points
- Tirzepatide at $275/month is higher than the cheapest compounded competitors
- The streak discount requires daily in-app meal logging — miss days and you pay full rate
- The compounding pharmacy partner is described as a LegitScript-certified 503A but not named
- Only two medications — compounded semaglutide and tirzepatide; no oral or non-GLP options
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.